Involvement of the peripheral nervous system in
mitochondrial disorders has been previously reported. However, the prevalence of
peripheral neuropathy in
mitochondrial disorders is still unclear. Based on the large database of the "Nation-wide Italian Collaborative Network of
Mitochondrial Diseases", we reviewed the clinical data of 1200 patients, with special regard to
peripheral neuropathy (mean age at onset 24.3 ± 20.1 years; age at last evaluation 39.8 ± 22.3 years; females 52.7%; childhood onset [before age 16 years] 43.1%).
Peripheral neuropathy was present in 143/1156 patients (12.4%), being one of the ten most common signs and symptoms. POLG mutations cause a potentially painful, axonal/mixed, mainly sensory
polyneuropathy; TYMP mutations lead to a demyelinating sensory-
motor polyneuropathy; SURF1 mutations are associated with a demyelinating/mixed sensory-
motor polyneuropathy. The only
mtDNA mutation consistently associated with
peripheral neuropathy (although less severely than in the above-considered nuclear genes) was the m.8993T > G (or the rarer T > C) changes, which lead to an axonal, mainly sensory
polyneuropathy. In conclusion,
peripheral neuropathy is one of the most common features of a
mitochondrial disorder, and may negatively impact on the quality of life of these patients. Furthermore, the presence or absence of
peripheral neuropathy, as well as its specific forms and the association with
neuropathic pain (indicative of a POLG-associated disease) can guide the molecular analysis.